Company profile
Micrima
Micrima have developed MARIA, a radiowave breast detection tool. Micrima are transforming the detection of breast cancer for all women, making a difference to the early diagnosis of breast cancer.
Reference milestones and recent Companies House filing stream events.
Next confirmation statement due date
Next accounts due date
SH01 | Transaction MzUxMjk2NzIzM2FkaXF6a2N4 | Paper/PDF filed
Published 01 Apr 2026 22:47
Last confirmation statement made up date
Last accounts made up date
CS01 | Transaction MzQ0MjU2NzQ0OWFkaXF6a2N4
Published 12 Nov 2024 05:20
AA | Transaction MzQzODMxNTU4NmFkaXF6a2N4 | Paper/PDF filed
Published 10 Oct 2024 06:23
Company registered at Companies House
1 Feb 2018 to 31 Jan 2020
How many females can you count within your family (if you are one, include yourself)? Grandmothers, mothers, wives, daughters, sisters, nieces, sisters in-law – the list goes on. Think wider: how many females are part of your group of friends? If the answer is 8 or more, statistics say that 1 of them will be diagnosed with breast cancer. Breast cancer has...
1 Aug 2017 to 31 Jul 2019
Breast cancer is the largest killer of women in the West, with over 0.5m dying from it each year despite the contribution of national screening programs which drive a >$1bn global market for diagnostic imaging systems. MARIA (Micrima Limited, Bristol) is a radiofrequency-based breast imaging system that does not utilise ionising radiation, requires limite...
1 Apr 2015 to 30 Jun 2017
The CCDMM project focuses on the development of imaging and characterization solutions targeting different markets which will be commercialized by 4 individual SMEs based on a disruptive microwave measurement platform developed by a large company. The outcomes of the project are technology prototypes ready to enter clinical trials. The target markets are:...
1 Nov 2013 to 31 Dec 2014
Micrima is developing radio wave radar technology for medical imaging applications. The primary application of this technology is in the assessment of breast cancer. The device emits a low-level, non-hazardous, non-ionising radiation signal into the tissue to be imaged and captures and analyses responses to the signal as they are bounced off of non-homoge...
